TY  - GEN
AU  - Olivieri,Ignazio
AU  - Fanizza,Caterina
AU  - Gilio,Michele
AU  - Ravasio,Roberto
TI  - Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis
SN  - 0392-856X
PY  - 2017///0127
KW  - Adalimumab
KW  - economics
KW  - Biological Products
KW  - adverse effects
KW  - Certolizumab Pegol
KW  - Cost-Benefit Analysis
KW  - Drug Costs
KW  - Etanercept
KW  - Humans
KW  - Models, Economic
KW  - Randomized Controlled Trials as Topic
KW  - Recovery of Function
KW  - Remission Induction
KW  - Sacroiliac Joint
KW  - diagnostic imaging
KW  - Spine
KW  - Spondylarthritis
KW  - Time Factors
KW  - Treatment Outcome
KW  - Tumor Necrosis Factor-alpha
KW  - antagonists & inhibitors
N1  - Publication Type: Journal Article; Review; Systematic Review
ER  -